Engineered cold virus cuts bladder tumor recurrence in Phase 3 trial
CG Oncology announced on Monday, Nov. 16, 2026, that its bladder cancer therapy cretostimogene lowered the risk of tumor recurrence by 68% compared with current medical practice. The randomized Phase 3 trial enrolled 367 patients with intermediate-risk bladder cancer, a localized form usually removed by minimally invasive surgery. The results come from the company's announcement.
The treatment is an engineered common cold virus that targets cells carrying a mutation found in bladder tumors. Doctors deliver it through a catheter straight into the bladder, where the virus enters mutated cancer cells, replicates, and bursts them.
This matters for health because recurrence drives the burden of this disease. Patients are monitored every three months, and each return can mean repeat surgery, with bladder function declining over time. A bladder-sparing option that cuts recurrence could mean fewer procedures and fewer lost bladders. The therapy is still in trials, not approved.
The full account sits with STAT's reporting by Adam Feuerstein.
Source: STAT
Many Minded